Alex Wasyl
Directeur Général chez CRx Bio Holdings LLC
Fortune : 76 230 $ au 30/04/2024
Profil
Alex Wasyl is the founder of Elevated Life Sciences, which was founded in 2009, where he holds the title of Managing Director.
He is also the founder of CRx Bio Holdings LLC.
Mr. Wasyl's former job was as the Chief Executive Officer & Director at Nexien BioPharma, Inc. from 2018 to 2020.
Mr. Wasyl received an undergraduate degree from The College of New Jersey.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
NEXIEN BIOPHARMA, INC.
5,65% | 25/09/2023 | 3 811 500 ( 5,65% ) | 76 230 $ | 30/04/2024 |
Postes actifs de Alex Wasyl
Sociétés | Poste | Début |
---|---|---|
CRx Bio Holdings LLC
CRx Bio Holdings LLC Pharmaceuticals: OtherHealth Technology CRx Bio Holdings LLC engages in the research and development of advanced cannabinoid therapeutic formulations with the objective of enhancing the bioavailability, pharmacokinetics, and pharmacodynamics of cannabinoids. The company was founded by Alex Wasyl and is headquartered in Princeton, NJ. | Directeur Général | - |
Elevated Life Sciences | Fondateur | 01/02/2009 |
Anciens postes connus de Alex Wasyl
Sociétés | Poste | Fin |
---|---|---|
NEXIEN BIOPHARMA, INC. | Directeur Général | 31/03/2020 |
Formation de Alex Wasyl
The College of New Jersey | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 3 |
---|---|
Nexien BioPharma, Inc. | |
CRx Bio Holdings LLC
CRx Bio Holdings LLC Pharmaceuticals: OtherHealth Technology CRx Bio Holdings LLC engages in the research and development of advanced cannabinoid therapeutic formulations with the objective of enhancing the bioavailability, pharmacokinetics, and pharmacodynamics of cannabinoids. The company was founded by Alex Wasyl and is headquartered in Princeton, NJ. | Health Technology |
Elevated Life Sciences |